NOTICE TO THE ANNUAL GENERAL MEETING OF DOVRE GROUP PLC
Dovre Group Plc Stock Exchange Release March 9, 2023 at 10 am
NOTICE TOTHE ANNUAL GENERAL MEETING OF DOVRE GROUP PLC
Notice is given to the shareholders of Dovre Group Plc (‘Company’) of the Annual General Meeting (‘AGM’) to be held on Thursday, March 30, 2023 at 2 pm at Helsingin Suomalainen Klubi (The Helsinki Finnish Club), Kansakoulukatu 3, 00100 Helsinki. The reception of the persons who have registered for the meeting and the distribution of voting tickets will commence at 1.30 p.m.
Shareholders representing over 32% of the outstanding shares of Dovre Group Plc have indicated that they will vote in favor of all proposals presented in this notice to the Annual General Meeting.
A. MATTERS ON THE AGENDA OF THE ANNUAL GENERAL MEETING
At the AGM, the following matters will be considered:
1. Opening of the meeting
2. Calling the meeting to order
3. Election of persons to confirm the minutes and to verify the counting of votes
4. Recording the legal convening of the meeting and quorum
5. Recording the attendance at the meeting and adoption of the voting list
6. Presentation of the annual accounts 2022, the report of the Board of Directors and the auditor's report
- Review by the CEO of Dovre Group Plc
- Review by the CEO of the Company’s subsidiary Suvic Oy
7. Adoption of the annual accounts
8. Resolution on the use of the profit shown on the balance sheet and resolution on the payment of dividend
The parent company’s distributable funds as on December 31, 2022 amounted to EUR 18,781,604.44. Board of Directors proposes to the Annual General Meeting that a dividend of EUR 0.01 per share be paid. The Board of Directors further proposes that the dividend is paid to a shareholder who on the record date April 3, 2023, is registered as a shareholder in the Company's shareholder register maintained by Euroclear Finland Ltd. The dividend is paid on April 12, 2023. It is stated that dividend is not paid to the shares owned by the company.
9. Resolution on the discharge of the members of the Board of Directors and the CEO from liability
10. Adoption of the remuneration report for the Company’s governing bodies
The Board of Directors proposes to the AGM that the Annual General Meeting adopts the remuneration report for the financial year of 2022.
11. Resolution on the remuneration of the members of the Board of Directors
The shareholders representing over 32% of the total shares in the Company propose to the AGM that the annual remuneration payable to the Board members shall be as follows: The chairman of the Board is paid EUR 40,000, the vice chairman of the Board EUR 33,000, and each other member of the Board EUR 25,000.
The shareholders also propose that reasonable travel expenses incurred by the Board members are compensated.
The remuneration of the members of the Board of Directors shall be paid in cash.
12. Resolution on the number of members of the Board of Directors
The shareholders representing over 32% of the total shares in the Company propose to the AGM that the number of Board members be set at four (4).
13. Election of the members of the Board of Directors
The shareholders representing over 32% of the total shares in the Company propose Ilari Koskelo, Antti Manninen, Sanna Outa-Ollila and Svein Stavelin, all current members of the Board, to be reappointed as members of the Board.
14. Resolution on the remuneration of the auditor
The Board of Directors proposes to the AGM that the auditor’s fee shall be paid according to the approved invoice from the auditor.
15. Election of the auditor
The Board of Directors proposes to the AGM that one auditor be elected for the Company. The Board of Directors proposes the election of Authorized Public Accountant firm BDO Oy as the Company’s auditor. BDO Oy has informed that Authorized Public Accountant Henrik Juth will be the auditor in charge.
16. Authorizing the Board of Directors to decide on the repurchase of the Company’s own shares
The Board of Directors proposes that the AGM resolves on authorizing the Board of Directors to decide on the repurchase of the Company’s own shares, on the following conditions:
a) By virtue of the authorization, the Board is entitled to decide on repurchase of a maximum of 10,100,000 of the Company’s own shares, corresponding to a maximum of approximately 9.5% of all shares in the Company.
b) The Company’s own shares may be repurchased in deviation from the proportion to the holdings of the shareholders using the non-restricted equity and acquired on regulated market through trading on Nasdaq Helsinki Ltd at the share price prevailing at the time of acquisition. Shares will be acquired and paid for in accordance with the rules of Nasdaq Helsinki Ltd and Euroclear Finland Ltd.
c) The shares may be repurchased in order to be used as consideration in possible acquisitions or other arrangements related to the Company’s business, to finance investments or as part of the Company’s incentive program or the be held, otherwise conveyed or cancelled by the Company.
The Board of Directors shall decide on other matters related to repurchase of the Company’s own shares.
The repurchase authorization is valid until June 30, 2024. The authorization revokes previous authorizations to acquire the Company’s own shares.
17. Authorizing the Board of Directors to decide on the issuance of shares as well as the issuance of other special rights entitling to shares
The Board of Directors proposes that the AGM would resolve on authorizing the Board of Directors to decide on
(i) the issuance of new shares and/or
(ii) the conveyance of the Company’s own shares and/or
(iii) the granting of special rights referred to in Chapter 10, Section 1 of the Finnish Companies Act, on the following conditions:
By virtue of the authorization, the Board may also decide on a directed issue of shares and special rights, i.e. in deviation of the pre-emptive subscription rights of the shareholders, under the requirements of the law. By virtue of the authorization, a maximum of 10,100,000 shares may be issued, corresponding to a maximum of 9.5% of the Company’s existing shares.
The Board may use the authorization in one or more instalments. The Board may use the authorization to finance or conclude acquisitions or other arrangements, to strengthen the Company’s capital structure, for incentive programs or for other purposes decided by the Board. The new shares may be issued or the Company’s own shares conveyed either against payment or free of charge. The new shares may also be issued as an issue without payment to the Company itself. The Board is authorized to decide on other terms of the issuance of shares and special rights. By virtue of the authorization, the Board of Directors may decide on the realization of the Company’s own shares possibly held by the Company as pledge.
The authorization is valid until June 30, 2024. The authorization revokes earlier authorizations to issue shares and grant option rights and other special rights entitling to shares.
18. Closing of the meeting
B. DOCUMENTS OF THE ANNUAL GENERAL MEETING
The above mentioned proposals of the Board of Directors relating to the agenda of the AGM as well as this notice are available on the Company’s website www.dovregroup.com. The Company’s annual report, which includes the Company’s financial statements, the report of the Board of Directors, the auditor’s report and the Corporate Government Statement, as well as the remuneration report, will be available on the above mentioned website during week 11. The proposals of the Board of Directors and the financial statements are also available at the AGM. Copies of these documents and of this notice will be sent to shareholders upon request.
C. INSTRUCTIONS FOR THE PARTICIPANTS IN THE ANNUAL GENERAL MEETING
1. The right to participate and registration
Each shareholder, who is registered on March 20, 2023 in the shareholders’ register of the Company held by Euroclear Finland Ltd, has the right to participate in the AGM. A shareholder, whose shares are registered on his/her personal Finnish book-entry account, is registered in the shareholder register of the Company.
The registration period for the general meeting commences on March 9, 2023. A shareholder, who is registered in the shareholder register of the Company and who wants to participate in the AGM, shall register for the meeting no later than March 27, 2023 10 a.m. by giving a prior notice of participation, which shall be received by the Company no later than on the above mentioned date and time.
Such notice can be given:
a) on Dovre Group Plc’s website at www.dovregroup.com
b) by email to email@example.com
c) by telephone to Dovre Group Plc/Marja Saukkonen, tel. +358 50 385 4296
In connection with the registration, a shareholder shall notify his/her name, personal identification number, address, telephone number, and the name of a possible assistant or proxy representative and the personal identification number of a proxy representative. The personal data given to Dovre Group Plc is used only in connection with the AGM and with the processing of related necessary registrations.
2. Holders of nominee registered shares
A holder of nominee registered shares has the right to participate in the AGM by virtue of such shares, based on which he/she would be entitled to be registered in the shareholder register of the Company held by Euroclear Finland Ltd on the record date of the AGM on March 20, 2023. The right to participate in the AGM requires, in addition, that the shareholder has, on the basis of such shares, been registered into the temporary shareholder register held by Euroclear Finland Ltd. at the latest by March 27, 2023 by 10 a.m. In regards to nominee registered shares this constitutes due registration for the AGM.
A holder of nominee registered shares is advised to request without delay necessary instructions regarding the registration in the temporary shareholder register of the Company, the issuing of proxy documents and registration for the AGM from his/her custodian bank. The account management organization of the custodian bank has to register a holder of nominee registered shares, who wants to participate in the AGM, into the temporary shareholder register of the Company at the latest by March 27, 2023 by 10 a.m.
3. Proxy representative and powers of attorney
A shareholder may participate in the AGM and exercise his/her rights at the meeting by way of proxy representation. A proxy representative shall produce a duly dated proxy document or otherwise in a reliable manner demonstrate his/her right to represent the shareholder at the AGM. When a shareholder participates in the AGM by means of several proxy representatives representing the shareholder with shares at different securities accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration for the AGM.
Any proxy documents should be delivered in original to Dovre Group Plc/Marja Saukkonen, Ahventie 4 B, 02170 Espoo, Finland, or as a scanned copy by email to firstname.lastname@example.org by the last date of registration.
4. Other information
Pursuant to Chapter 5, Section 25 of the Companies Act, a shareholder who is present at the AGM has the right to request information with respect to the matters to be considered at the meeting
On the date of this notice to the AGM, March 9, 2023, the total number of shares and votes in Dovre Group Plc is 105,956,494.
Espoo, March 9, 2023
DOVRE GROUP PLC
Board of Directors
For further information please contact Mr Arve Jensen, CEO, tel. +47 90 60 78 11 or Ms Sirpa Haavisto, CFO, tel. +358 20 436 2000.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Multitude Group Annual Report for 2022 published30.3.2023 22:45:00 CEST | Press release
Multitude Group Annual Report for 2022 published Helsinki, 30 March 2023 – Multitude SE (ISIN: FI4000106299, WKN: A1W9NS) (“Multitude” or the “Group”) is pleased to announce that the Group's Annual Report, Corporate Governance Statement and Remuneration Report for the year ended 31 December 2022 have been published today on the company’s website. The Annual Report consists of annual review and financial review, including Board of Directors‘ report, consolidated financial statements and parent company’s financial statements. The annual review includes the ESG Report 2022 which comprises the non-financial statement. It outlines the Group’s ESG Goals and KPIs focused on people, processes, and the environment, with commencement of reporting on the Group’s carbon emissions. The ESG report 2022 further highlights the Group’s commitment to customer well-being through responsible lending practices and the introduction of a Responsible Lending Index and a commitment to progress on employee well
Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion30.3.2023 22:45:00 CEST | Press release
Company announcement – No. 11 / 2023 Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT; ANY PUBLIC OFFERING OF SUCH SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM THE ISSUER, WHICH WOULD CONTAIN DETAILED INFORMATION ABOUT THE COMPANY AND MANAGEMENT, AS WELL AS FINANCIAL STATEMENTS. As announced on 30 March 2023, Zealand Pharma commenced
Multitude SE: Notice to Convene Multitude SE's Annual General Meeting of Shareholders30.3.2023 22:45:00 CEST | Press release
NOTICE TO CONVENE MULTITUDE SE’S ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is given to the shareholders of Multitude SE (Company) that the Annual General Meeting of the Company is to be held on 27 April 2023 at 10:00 a.m. (EEST / Finnish time) at the offices of Castrén & Snellman Attorneys Ltd, Eteläesplanadi 14, Helsinki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will start at 9:30 a.m. (EEST / Finnish time). Shareholders may also exercise their voting rights by voting in advance. Instructions concerning advance voting are provided in Section 3.4 of this notice. It will not be possible to participate in the meeting or follow the meeting via an online stream or otherwise in real time by the use of telecommunication connections or technical means. The meeting will be held in the English language. 1 MATTERS ON THE AGENDA OF THE GENERAL MEETING OF SHAREHOLDERS At the General Meeting of Shareholders, the following matte
Galapagos and NovAliX enter into an integrated drug discovery collaboration30.3.2023 22:30:00 CEST | Press release
Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery focused Contract Research Organization (CRO) based in Strasbourg, FranceNovAliX to assume Galapagos’ research capabilities, and Galapagos retains flexibility to access necessary expertise and resources through a five year-collaboration agreementTransaction in the context of Galapagos’ strategic reset announced in 2022; closing expected in July 2023 Mechelen, Belgium and Strasbourg, France; 30March 2023, 22.01 CET; GalapagosNV (Euronext & NASDAQ: GLPG)and NovAliXtoday announceda strategic collaborationin which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred toNovAliX, a drug discovery-focused Contract Research Organization. The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology, and the strategic reorientationof the company into a fit-for-purpose
ResMed Chief Administrative Officer and Global General Counsel to Retire30.3.2023 22:05:00 CEST | Press release
ResMed to conduct an internal search for a successor general counselAmy Wakeham appointed Chief Communications and Investor Relations Officer, will join ResMed’s executive leadership team SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023. He will remain in a consulting role with ResMed through December 31, 2023. ResMed will conduct an internal search for the successor to Pendarvis’ legal roles and expects to name a new global general counsel and secretary well ahead of David’s retirement date to ensure a smooth and seamless transition. Amy Wakeham, ResMed’s current Vice President of Corporate Communications & Investor Relations, has been appointed Chief Communications and Investor Relations Officer to succeed Pendarvis in his role leading corporate public affairs; she will report to the Office of the CEO and will jo